Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Oncopeptides AB ( (SE:ONCO) ) is now available.
Oncopeptides AB reported a strong performance in the second quarter of 2025, with net sales reaching SEK 19.2 million, marking a 135% increase compared to the same period last year. The company attributes this growth to robust organic growth in Germany and faster-than-expected market access in Spain and Italy. Significant developments include the inclusion of their drug Pepaxti in European treatment guidelines for multiple myeloma and the lifting of a clinical hold by the U.S. FDA. These achievements are expected to enhance Oncopeptides’ market position and support its goal of reaching profitability by the end of 2026.
The most recent analyst rating on (SE:ONCO) stock is a Hold with a SEK5.00 price target. To see the full list of analyst forecasts on Oncopeptides AB stock, see the SE:ONCO Stock Forecast page.
More about Oncopeptides AB
Oncopeptides AB is a biotech company that specializes in developing treatments for difficult-to-treat cancers. The company is particularly focused on the European market, with significant growth in Germany, Spain, and Italy.
Average Trading Volume: 4,992,271
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.13B
Learn more about ONCO stock on TipRanks’ Stock Analysis page.